Actively Recruiting
Open-Label Phase 12 Study Evaluating Safety and Efficacy of Dibotatug DR-01 in Adults with Bone Marrow Failure Syndromes
Led by Dren Bio · Updated on 2026-11-04
60
Participants Needed
10
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety and effectiveness of Dibotatug DR-01 in adults with Bone Marrow Failure syndromes, including Severe Aplastic Anemia SAA and Non-severe Aplastic Anemia NSAA. The study is an open-label Phase 12 trial enrolling patients across three groups refractory SAA, relapsed SAA, and relapsed or refractory transfusion-dependent NSAA. Participants receive Dibotatug through intravenous infusion in a single treatment arm lasting 20 weeks. Those who respond with a complete or partial response by Week 24 may continue treatment up to Week 48. The study is conducted in two stages, starting with safety and preliminary efficacy evaluation in at least 12 participants, and potentially expanding to 60 participants total. During the study, participants undergo regular assessments including monitoring for treatment response and adverse events up to 52 weeks. Researchers measure the overall response rate defined by complete or partial responses by six months and track side effects using standardized criteria. The trial lasts until October 2030, with continued safety follow-up and optional extended treatment for responders.
CONDITIONS
Brief Title
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
Research Team
D
Dren Bio Central Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here